• Myriad Genetics approved one-time executive stock option awards on November 6, 2026, under its 2026 Employee, Director and Consultant Equity Incentive Plan.
• Chief Operating Officer Mark S. Verratti received options covering 146,933 shares.
• Chief Financial Officer Benjamin R. Wheeler received options covering 121,379 shares.
• Chief Scientific Officer Dale Muzzey received options covering 92,632 shares.
• The options vest on the grant date’s third anniversary, subject to continued service, with 10-year terms subject to earlier termination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-072114), on November 09, 2026, and is solely responsible for the information contained therein.